Preprocedural statin therapy in percutaneous coronary intervention

Area of Science:

• Cardiology
• Pharmacology

Background:

• Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used for cardiovascular event prevention.
• Statins offer pleiotropic effects beyond lipid-lowering, including plaque stabilization and anti-inflammatory actions.

Purpose of the Study:

• To review existing literature on the efficacy of preprocedural statin therapy in preventing cardiac events post-percutaneous coronary intervention (PCI).

Main Methods:

• Searched MEDLINE and Cochrane databases for English-language studies on statins and PCI.
• Included retrospective analyses, observational studies, and randomized controlled trials evaluating preprocedural statin use.
• Focused on studies assessing cardiac events and myocardial necrosis after PCI.

Main Results:

• The reviewed studies suggest that preprocedural statin therapy may reduce myocardial necrosis following elective PCI in stable patients and those with acute coronary syndrome.
• Limitations included small sample sizes, short follow-up durations, and varied study methodologies.

Conclusions:

• Growing evidence indicates preprocedural statin therapy can decrease post-PCI myocardial necrosis.
• Optimal drug, dose, and duration of statin therapy require further investigation, as does the role of conditions like hyperlipidemia.